T cell engager (TCE) score in patients treated with bispecific CD3 TCE in phase I clinical trials

被引：0
|
作者：
Herbel, Noe
Goldschmidt, Vincent
Michot, Jean-Marie
Laparra, Ariane
Geraud, Arthur
Ouali, Kaissa
Danlos, Francois-Xavier
Vuagnat, Perrine
Bernard-Tessier, Alice
Gazzah, Anas
Bahleda, Rastilav
Hollebecque, Antoine
Marabelle, Aurelien
Postel-Vinay, Sophie
Loriot, Yohann
Massard, Christophe
Ribrag, Vincent
Aix, Santiago Ponce
Champiat, Stephane
Baldini, Capucine
机构：
[1] Gustave Roussy, Drug Dev Dept DITEP, Villejuif, France
[2] Gustave Roussy, Dept Interdisciplinaire Org Parcours Patient DIOP, Villejuif, France
[3] Gustave Roussy Inst, Med Oncol Dept, Villejuif, France
[4] Gustave Roussy, Drug Dev Dept, Canc Campus, Villejuif, France
[5] Gustave Roussy, Drug Dev Dept, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2573
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials
    Herbel, N.
    Ouali, K.
    Danlos, F-X.
    Massard, C. P.
    Goldschmidt, V.
    Michot, J-M.
    Laparra, A.
    Bernard-Tessier, A.
    Gazzah, A.
    Bahleda, R.
    Hollebecque, A.
    Henon, C.
    Postel-Vinay, S.
    Loriot, Y.
    Ribrag, V.
    Marabelle, A.
    Fizazi, K.
    Aix, S. Ponce
    Champiat, S.
    Baldini, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S519 - S519
  • [2] The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm
    Suurs, Frans, V
    Lorenczewski, Grit
    Stienen, Sabine
    Friedrich, Matthias
    de Vries, Elisabeth G. E.
    de Groot, Derk Jan A.
    Lub-de Hooge, Marjolijn N.
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (11) : 1594 - 1601
  • [3] Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies
    Reed, Daniel R.
    Lum, Lawrence G.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (08) : 761 - 772
  • [4] Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma
    Sangsuwannukul, Thanich
    Supimon, Kamonlapat
    Chieochansin, Thaweesak
    Choomee, Kornkan
    Sujjitjoon, Jatuporn
    Junking, Mutita
    Yenchitsomanus, Pa-Thai
    PLOS ONE, 2022, 17 (03):
  • [5] Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
    Goebeler, Maria-Elisabeth
    Bargou, Ralf
    LEUKEMIA & LYMPHOMA, 2016, 57 (05) : 1021 - 1032
  • [6] FDA approves first DLL3 x CD3 bispecific T-cell engager for lung cancer
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (07) : 487 - 487
  • [7] Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo
    G. de Jong
    L. Bartels
    M. Kedde
    E. M. E. Verdegaal
    M. A. Gillissen
    S. E. Levie
    M. G. Cercel
    S. E. van Hal-van Veen
    C. Fatmawati
    D. van de Berg
    E. Yasuda
    Y. B. Claassen
    A. Q. Bakker
    S. H. van der Burg
    R. Schotte
    J. Villaudy
    H. Spits
    M. D. Hazenberg
    P. M. van Helden
    K. Wagner
    Cancer Immunology, Immunotherapy, 2021, 70 : 1569 - 1581
  • [8] Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
    Wu, Jingjing
    Fu, Jiaping
    Zhang, Mingzhi
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [9] Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
    Jingjing Wu
    Jiaping Fu
    Mingzhi Zhang
    Delong Liu
    Journal of Hematology & Oncology, 8
  • [10] CD123-CODV-TCE bispecific T-cell engager for acute myeloid leukemia (AML): Activity on primary AML and safety in non-human primates
    Bonnevaux, Helene
    Courta, Jacqueline
    Passe-Coutrin, Wilfried
    Bauchet, Anne-Laure
    Roobrouck, Annelies
    Amara, Celine
    Beys, Eric
    Balzano, Marielle
    Moulard, Maxime
    Meloni, Marco
    Dullaers, Melissa
    Chiron, Marielle
    Virone-Oddos, Angela
    CANCER RESEARCH, 2022, 82 (12)
12345